Westhampton Capital LLC Increases Stake in Pfizer Inc. $PFE

Westhampton Capital LLC increased its position in Pfizer Inc. (NYSE:PFE) by 9.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 46,778 shares of the biopharmaceutical company’s stock after acquiring an additional 4,200 shares during the quarter. Westhampton Capital LLC’s holdings in Pfizer were worth $1,134,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the 1st quarter valued at about $27,000. North Capital Inc. purchased a new position in Pfizer during the 1st quarter valued at about $28,000. Bayforest Capital Ltd purchased a new position in Pfizer during the 1st quarter valued at about $28,000. Horizon Financial Services LLC purchased a new position in Pfizer during the 1st quarter valued at about $35,000. Finally, WPG Advisers LLC purchased a new position in Pfizer during the 1st quarter valued at about $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent analyst reports. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday. Morgan Stanley boosted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Price Performance

Shares of Pfizer stock opened at $23.84 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market cap of $135.54 billion, a PE ratio of 12.68, a P/E/G ratio of 0.77 and a beta of 0.55. The business has a 50 day moving average of $24.54 and a 200 day moving average of $24.11. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.